NASDAQ$URGN
UroGen Pharma Ltd · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
UroGen's Q1 2023 earnings were released, showing revenue growth driven by JELMYTO sales.
UroGen Pharma reported a net product revenue of $17.2 million for JELMYTO in Q1 2023, representing a ~27% increase compared to Q1 2022. The company is preparing for topline results from the ENVISION and ATLAS clinical trials and anticipates submitting an NDA for UGN-102 in 2024.
- JELMYTO net product revenues reached $17.2 million in Q1 2023, a ~27% increase year-over-year.
- Topline data readout from the ENVISION pivotal trial and ATLAS trial are expected in summer 2023.
- The company plans to submit a New Drug Application for UGN-102 in 2024.
- A study showed UGN-102 was suitable to administer at home by a visiting nurse under the supervision of a treating physician and resulted in 75% (n=8) of patients achieving a complete response.
Headline financials
Revenue & EPS history
UroGen · Revenue · Quarterly
$17.2M
Revenue by segment
UroGen · $17.2M total across 1 segment · Q1 2023
- JELMYTO$17.2M—100.0%
Forward guidance
UroGen Pharma provides financial guidance for the full year 2023.
Tailwinds
- Net product revenues from JELMYTO are anticipated to be in the range of $76 to $86 million.
- The company anticipates submitting an NDA for UGN-102 in 2024, based on positive findings from ongoing trials.
- Guidance includes anticipated full year 2023 net product revenues from JELMYTO to be in the range of $76 to $86 million.
- Operating expenses are expected to range from $135 to $145 million.
- The company anticipates full year 2023 non-cash financing expense related to the prepaid obligation to RTW Investments in the range of $21.0 to $26.0 million.
Headwinds
- Operating expenses are projected to be between $135 to $145 million for the full year.
- Non-cash financing expense related to the prepaid obligation to RTW Investments is expected to be in the range of $21.0 to $26.0 million.
- Approximately $9.9 to $11.2 million of the RTW Investments expense is expected to be in cash.
- Unforeseen delays may impact the timing of progressing clinical trials and reporting data.
- UroGen's financial condition and need for additional capital in the future may pose risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-1.5%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-4.5%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+22.0%
Q3 2025
Best reaction
-28.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.2% | +31.3% | +12.6% | |
| Q4 2025 | -12.4% | -5.7% | -12.7% | |
| Q3 2025 | +22.0% | +22.4% | +19.0% | |
| Q1 2025 | +7.1% | -29.6% | -29.7% | |
| Q4 2024 | +1.0% | +12.7% | +2.9% | |
| Q3 2024 | -0.9% | +4.8% | +0.7% | |
| Q2 2024 | +3.0% | +2.0% | -10.1% | |
| Q1 2024 | +1.8% | +3.8% | -0.2% | |
| Q4 2023 | -17.2% | -14.0% | -13.6% | |
| Q3 2023 | -1.5% | +6.0% | +29.6% | |
| Q2 2023 | +7.1% | +8.0% | -20.0% | |
| Q1 2023 | +4.8% | +2.2% | +1.3% | |
| Q4 2022 | -11.7% | -9.1% | +0.0% | |
| Q3 2022 | -18.8% | -17.2% | -27.6% | |
| Q2 2022 | -4.3% | -5.5% | -11.4% | |
| Q1 2022 | -2.7% | -4.0% | +13.1% | |
| Q4 2021 | -1.9% | -4.4% | -17.3% | |
| Q3 2021 | -28.7% | -37.0% | -46.9% | |
| Q2 2021 | -1.1% | -1.8% | +14.1% | |
| Q1 2021 | -16.3% | -2.9% | -4.7% | |
| Q4 2020 | +2.4% | -0.3% | -5.9% | |
| Q3 2020 | +0.3% | -1.9% | -22.8% | |
| Q2 2020 | +4.4% | -0.9% | -7.7% | |
| Q1 2020 | -0.2% | +2.8% | +13.4% | |
| Q4 2019 | +6.8% | +6.8% | -39.5% | |
| Q3 2019 | +8.0% | +9.7% | +37.9% | |
| Q2 2019 | -1.2% | -0.7% | +2.2% | |
| Q1 2019 | +3.6% | +1.9% | -1.7% | |
| Q4 2018 | +4.1% | +3.3% | -3.8% | |
| Q3 2018 | +0.7% | +1.0% | -0.3% | |
| Q2 2018 | -10.0% | -7.1% | -3.7% | |
| Q1 2018 | +1.8% | +6.0% | -9.9% | |
| Q4 2017 | -5.8% | -7.5% | +3.0% | |
| Q3 2017 | -3.9% | -5.2% | -14.2% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro